Alcon has received FDA approval for the AcrySof ReSTOR intraocular lens (IOL) for the correction of aphakia following cataract surgery in patients with or without presbyopia.
Alcon has received FDA approval for the AcrySof ReSTOR intraocular lens (IOL) for the correction of aphakia following cataract surgery in patients with or without presbyopia.
The apodized, diffractive aspheric IOL is the only FDA approved presbyopia-correcting lens that incorporates aspheric optics into its design.
Alcon will commence a phased launch of AcrySof ReSTOR after necessary consignment quantities are established, with full distribution expected by the middle of the year.
COPHy 2023: Restorative therapies and the path to them
March 24th 2023In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.
APAO 2023: Keralink Trial and efficacy safety of corneal cross-linking for children with Keratoconus
February 25th 2023The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.
2 Clarke Drive
Cranbury, NJ 08512